the type 2 immune response -a manipulative exit strategy ... · 3 cryptococcus neoformansinfection....
TRANSCRIPT
The Type 2 immune response - a manipulative exit strategy for
Cryptococcus neoformans
Pavithra Ramakrishnan
T35 Medical Student Summer Immunology ProgramNielsen Laboratory 2019
Global burden of HIV associated cryptococcal meningitis
• Leading infectious cause of death in individuals with AIDS
• 15% of AIDS-related mortality globally• Uganda accounts for 60% of adult
meningitis
• Mortality rate is 65%, even with treatment
Rajasingham et al., 2017
CNS DiseaseDisseminationInitial LungInfection
EnvironmentalExposure
CFU
s
Time
Clearance
3
Cryptococcus neoformans infection
CNS DiseaseDisseminationInitial LungInfection
EnvironmentalExposure
CFU
s
Time
LatencyClearance
4
Cryptococcus neoformans infection
CNS DiseaseDisseminationInitial LungInfection
EnvironmentalExposure
CFU
s
Time
LatencyClearance
5
Cryptococcus neoformans infection
CNS DiseaseDisseminationInitial LungInfection
EnvironmentalExposure
CFU
s
Time
AcuteLatencyClearance
6
Cryptococcus neoformans infection
CNS DiseaseDisseminationInitial LungInfection
EnvironmentalExposure
CFU
s
Time
AcuteLatencyClearance
7
Cryptococcus neoformans infection
CNS DiseaseDisseminationInitial LungInfection
EnvironmentalExposure
8
Cryptococcus neoformans infection
What traits allow Cryptococcus to cause disease in the host?
How does the host prevent infection?
�����
�
Extracellular Pathogens
Intracellular Pathogens
ParasitesFungi
Wound healing
����
Mammalian CD4 T-cell differentiation impacts patient mortality
Modified from May et al., 2016 Nat Rev Micro
Type 1
Type 2
Low Mortality
�����
�
ParasitesFungi
Wound healing
Extracellular Pathogens
Intracellular Pathogens
Type 1
Type 2
High Mortality
����
Modified from May et al., 2016 Nat Rev MicroBoulware et al., 2010 PLoS Med
Mammalian CD4 T-cell differentiation impacts patient mortality
Modulation of the immune response by Cryptococcustitan cells
May et al., 2016
?
Hypothesis
Cryptococcus survives within and disseminates using M2 macrophages produced by titan cell-induced Th2 proliferation.
• Does titan cell induced Th2 response drive M2 macrophage polarization in vivo?
• Are M2 macrophages required for dissemination and crossing of the BBB via a trojan horse mechanism?
Experimental setup and gating strategy
Day 0 Day 14
Harvest: BALIsolate Leukocytes for flow cytometry
5x104
KN99αIntranasal
Day 3
Day 9
Day 6
Day 13
• Th2 response drives M2 macrophage polarization in vivo
• CD11b+ CD11c+ CD24+ dendritic cells predominate in the lung over the course of acute infection
CD 6
4
CD 24
CD 11b
CD 11c
Arg1RELMαCD71
CD 80/86
YFP
mcherry
Macrophages
Dendritic Cells
ArgYFP mice infected with mCherry-expressing Cryptococcusshow phagocytosis by type 2 cells in the lungs
Monocytes
Dendritic Cells
ArgYFP mice infected with mCherry-expressing Cryptococcusshow phagocytosis by type 2 cells in the lungs AND BLOOD
CD 1
15
CD 24
Arg1RELMαCD71
CD 80/86
YFP
mcherry
Results
• M2 polarization of macrophages is observed in the lungs during acute Cryptococcus infection.
• A large population of dendritic cells that may also be type 2 polarized is also produced during the acute infection in the lungs and could be another population that is involved in dissemination of Cryptococcus.
• Several populations of type 2 monocytes are present in blood that contain Cryptococcus.
Future work
• Develop a gating strategy to analyze dendritic cell subsets in BAL, blood and mediastinal lymph nodes
• Develop fluorescently labelled reporter strains of latent Cryptococcus neoformans strains that do not disseminate and may produce an M1 polarized immune response
• Test the therapeutic effects of various strategies that mute the type 2 immune response
Re-programming the immune response
Potentiating Type 1• Harrison et al., 2012
• IFNγ adjunctive short course therapy reduced CSF fungal burden in HIV associated cryptococcal meningitis
• was not associated with adverse events
• BUT did not improve patient survival
May et al., 2016
Re-programming the immune response
Blocking Type 2• Anti-IL13/IL4 mAb therapy
• Already FDA approved for asthma therapy (Regeneron)
Acknowledgements
Dr. Kirsten Nielsen Jackson EdgellMarina Yoder
Dr. Sophie Altamirano
Dr. Jesse Williams Dr. Tanya Freedman
Dr. Kaylee Schwertfeger
Dr. Daniel MuellerStephanie Krischuk
Thank you!
Are M2 macrophages required for dissemination and crossing the BBB via trojan horse mechanism?
Strain Dissemination Disease Th response MØ activation statusKN99α + + Th2 M2∆gpr4∆gpr5 - - Th2 M2UGCL 552 - - Th1 M1UGCL 223 + - Th1 M1